相关实验视频

Updated: May 12, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

11.9K

利拉格卢提德在经过卵巢切除的Wistar大鼠中阻止了身体和脂肪质量的增加

Camila Lüdke Rossetti1, Iris Soares Andrade2, Luiz Fernando Fonte Boa2

  • 1Instituto de Biofísica Carlos Chagas Filho, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, Brazil; Department of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, Miller School of Medicine, University of Miami, Miami, USA.

Molecular and cellular endocrinology
|September 21, 2024
PubMed
概括

葡萄糖类-1 (GLP-1) 激动剂利拉格胺在卵巢切除的老鼠中部分逆转了由雌激素缺乏引起的代谢障碍,但增加了脂肪组织的炎症.

关键词:
在 DPP-IV 中,利拉格卢提德 (Liraglutide) 是一种类药物.进行卵巢切除术.白色脂肪组织的脂肪组织.

更多相关视频

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

12.1K
Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies06:27

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

686

相关概念视频

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...